GlobeNewswire: Genomoncology Contains the last 10 of 2 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T00:01:19ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2017/06/27/1029546/0/en/UCSF-Enhances-Cancer-Assay-with-Interpretive-Reporting-Powered-by-GenomOncology-s-GO-Clinical-Workbench.html?f=22&fvtc=4&fvtv=31914UCSF Enhances Cancer Assay with Interpretive Reporting Powered by GenomOncology’s GO Clinical Workbench2017-06-27T13:00:00Z<![CDATA[CLEVELAND, June 27, 2017 (GLOBE NEWSWIRE) -- GenomOncology today announced that UC San Francisco (UCSF) is now utilizing the GO Clinical Workbench for rapid analysis and reporting of results from the “UCSF500,” an advanced next-generation sequencing panel used by researchers and physicians at the UCSF Helen Diller Family Comprehensive Cancer Center for precision cancer diagnosis and treatment.]]>https://www.globenewswire.com/news-release/2017/03/07/932867/0/en/GenomOncology-and-med-fusion-announce-the-addition-of-PD-L1-Testing-and-Interpretation-to-the-LungSEQ-and-50SEQ-Plus-FISH-Tests.html?f=22&fvtc=4&fvtv=31914GenomOncology and med fusion announce the addition of PD-L1 Testing and Interpretation to the LungSEQ® and 50SEQ® Plus FISH Tests2017-03-07T14:00:00Z<![CDATA[CLEVELAND, March 07, 2017 (GLOBE NEWSWIRE) -- med fusion, a Texas Oncology and The US Oncology Network preferred laboratory, and GenomOncology announce the expansion of med fusion’s LungSEQ® and 50SEQ® Plus FISH (for NSCLC) laboratory services to include PD-L1 expression testing. The panels will now help guide treatment selection of immunotherapeutic checkpoint inhibitors for metastatic non-small cell lung cancer (NSCLC).]]>